Transcription of ANNUAL REPORT 2017 - viforpharma.com
{{id}} {{{paragraph}}}
Example: bankruptcy
ANNUAL REPORT 2017 - viforpharma.com
ANNUAL . REPORT . 2017 . ANNUAL REPORT 2017 . AT A GLANCE. Guidance raised at half - year , continued good performance in H2. led to strong full- year results Net sales CHF 1, million, up on a constant currency basis EBITDA CHF million, up excluding Veltassa launch costs Cash net of debt of CHF million Transformation into a pure-play pharmaceutical company successfully completed Separation of Galenica Sant via initial public offering (IPO). Etienne Jornod re-elected as Executive Chairman with remuneration exclusively in shares blocked until 2020.
2 172 Vifor Pharma Ltd. Annual Report 2017 AT A GLANCE ANNUAL REPORT 2017 Guidance raised at half-year, continued good performance in H2 led to strong full-year results › Net sales CHF 1,342.1 ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: